Hanmi Pharm vows to make inroads to European market

Published: 2004-03-30 06:57:00

Updated: 2004-03-30 06:57:00

Hanmi Pharm has recently won market authorizations of its first generic antibiotic ceftazidime from the UK and Germany, following ceftriaxone and cefotaxime and vowed to push up with its plan to make quicker inroads to European market during the second quarter of this year.

The company has so ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK